WilliamENovotnyMD

Pediatrics • Greenville, NC

Pediatric Critical Care Medicine, Adolescent Medicine

Brody School of Medicine

Join to view full profile

Dr. Novotny is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Novotny's full profile

Already have an account?

Office
2150 Herbert Ct
Greenville, NC 27834
Phone+1 252-744-5437

Fax+1 252-744-1514

Education & Training

Sparrow HospitalResidency, Pediatrics, 1984 - 1985
St Louis University School of MedicineInternship, Transitional Year, 1981 - 1982
The University of Toledo College of MedicineClass of 1981

Certifications & Licensure

NC State Medical License 1993 - 2025
OH State Medical License 1994 - 1996
NY State Medical License 1989 - 1994
MI State Medical License 1984 - 1990
American Board of Pediatrics Pediatrics
American Board of Pediatrics Pediatric Critical Care Medicine

Clinical Trials

The Effect of Moderate CYP3A Inducer Rifabutin on the Pharmacokinetics of Zanubrutinib in Healthy Males Start of enrollment: 2020 Jul 29
Completed
Phase 1
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies Start of enrollment: 2020 Nov 15
Completed
Phase 1

Publications & Presentations

PubMed

Intranasal Dexmedetomidine Administration Precipitates Respiratory Failure in Child With Croup and Asthma.
William E Novotny, Pam Fox, Dynita Haislip
Clinical Case Reports. 2024-12-01
The potential effect of metabolic alkalosis on insulin sensitivity in an adolescent with new‐onset type 1 diabetes
William E Novotny, Irma Fiordalisi, Cynthia P Keel, Glenn D. Harris
Clinical Case Reports. 2021-05-01
Why humans should not eat broom straws: Pericarditis and endocarditis.
William E Novotny, Cynthia P Keel
Annals of Pediatric Cardiology. 2020-05-01

Lectures

Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Mantle Cell Lymphoma from a Phase 2 Trial
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Updated Safety and Activity of the Investigational Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-) in Patients with Mantle Cell Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018